Potential of Pegylated Interferon Alpha-2a in Behçet Uveitis: A Report of Five Cases

Ocul Immunol Inflamm. 2016 Oct;24(5):599-602. doi: 10.3109/09273948.2015.1010652. Epub 2015 Mar 11.

Authors

Philip Bielefeld¹, Hervé Devilliers¹, Clémence Deschasse², David Saadoun³, Pascal Sève⁴, Aurore Muselier¹, Catherine Creuzot-Garcher², Jean-François Besancenot¹, Alain Marie Bron²

Affiliations

¹ a Department of Internal Medicine and Systemic Diseases , University Hospital , Dijon , France .
² b Department of Ophthalmology , University Hospital , Dijon , France .
³ c Department of Internal Medicine 1 , Groupe Hospitalier Pitié-Salpétrière , Paris , France , and.
⁴ d Department of Internal Medicine , Hospices Civils de Lyon, Hôpital de la Croix-Rousse , Lyon , France.

PMID: 25760915
DOI: 10.3109/09273948.2015.1010652

No abstract available

Publication types

Case Reports

MeSH terms

Adult
Antiviral Agents / therapeutic use*
Behcet Syndrome / diagnosis
Behcet Syndrome / drug therapy*
Behcet Syndrome / physiopathology
Female
Humans
Injections, Subcutaneous
Interferon-alpha / therapeutic use*
Male
Middle Aged
Polyethylene Glycols / therapeutic use*
Recombinant Proteins / therapeutic use
Visual Acuity / physiology

Substances

Antiviral Agents
Interferon-alpha
Recombinant Proteins
Polyethylene Glycols
peginterferon alfa-2a